» Articles » PMID: 35597301

Long Non-coding RNA CYTOR Modulates Cancer Progression Through MiR-136-5p/MAT2B Axis in Renal Cell Carcinoma

Overview
Specialties Pharmacology
Toxicology
Date 2022 May 21
PMID 35597301
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To explore the role of long noncoding RNAs (lncRNAs) cytoskeleton regulator RNA (CYTOR) in renal cell carcinoma (RCC).

Methods: The levels of CYTOR in RCC tissues and cell lines were detected by RT-qPCR. 786-O and Caki-1 cells were transfected with CYTOR-shRNA or pcDNA-CYTOR respectively, or co-transfected with CYTOR-shRNA and miR-136-5p inhibitor, or co-transfected with miR-136-5p mimic and pcDNA-MAT2B. MTT assay, Transwell assay and flow cytometry were used to evaluate cell proliferation, invasion and apoptosis. The relationship between lncRNA CYTOR and miRNA-136-5p was detected by dual luciferase reporter gene and RNA pull down assays, and the targeted relationship between miRNA-136-5p and MAT2B was verified by dual luciferase reporter gene assay. The interaction between MAT2B and BAG3 protein was verified by co-IP experiment. The role of lncRNA CYTOR in vivo was also examined.

Results: LncRNA CYTOR was up-regulated in RCC tissues and cell lines, and miR-136-5p was down-regulated in renal carcinoma cell lines and tissues. Downregulation of CYTOR inhibited cell proliferation and invasion and promoted apoptosis. miR-136-5p was sponged by lncRNA CYTOR, which negatively regulated the development of RCC. MAT2B was a target gene of miR-136-5p. MAT2B protein interacted directly with BAG3 protein to affect the proliferation, invasion and apoptosis of RCC cells. In vivo experiments showed that the expression level of miR-136-5p was increased, and MAT2B expression was decreased after CYTOR knockdown, thereby inhibiting the development of RCC.

Conclusions: LncRNA CYTOR promoted the progression of RCC by targeting miR-136-5p to regulate the target gene MAT2B, which interacted with BAG3 protein.

Citing Articles

Exploring the dual role of endoplasmic reticulum stress in urological cancers: Implications for tumor progression and cell death interactions.

Farahani N, Alimohammadi M, Raei M, Nabavi N, Aref A, Hushmandi K J Cell Commun Signal. 2024; 18(4):e12054.

PMID: 39691874 PMC: 11647052. DOI: 10.1002/ccs3.12054.


Current insights and future directions of LncRNA Morrbid in disease pathogenesis.

Yang H, Gao J, Zheng Z, Yu Y, Zhang C Heliyon. 2024; 10(17):e36681.

PMID: 39263145 PMC: 11388785. DOI: 10.1016/j.heliyon.2024.e36681.


Exploring the Therapeutic Significance of microRNAs and lncRNAs in Kidney Diseases.

Bravo-Vazquez L, Paul S, Colin-Jurado M, Marquez-Gallardo L, Castanon-Cortes L, Banerjee A Genes (Basel). 2024; 15(1).

PMID: 38275604 PMC: 10815231. DOI: 10.3390/genes15010123.


High C1QTNF1 expression mediated by potential ncRNAs is associated with poor prognosis and tumor immunity in kidney renal clear cell carcinoma.

Qiu J, Wang Z, Zhao L, Zhang P, Xu Y, Xia Q Front Mol Biosci. 2023; 10:1201155.

PMID: 37529377 PMC: 10387556. DOI: 10.3389/fmolb.2023.1201155.


Six-transmembrane epithelial antigen of prostate 3 (STEAP3) is a potential prognostic biomarker in clear cell renal cell carcinoma that correlates with M2 macrophage infiltration and epithelial-mesenchymal.

Wei H, Li Z, Zhao Y, Zhu S, Wen S, Quan C Cancer Rep (Hoboken). 2023; 6(8):e1824.

PMID: 37344930 PMC: 10432435. DOI: 10.1002/cnr2.1824.